Paolo Ascierto, Director of the Department of Melanoma, Cancer Immunotherapy and Development Therapeutics at the National Cancer Institute IRCCS Pascale Foundation, shared on LinkedIn:
“Another successful edition of INNOVATE!
We have just concluded the third edition of INNOVATE, our international meeting dedicated to neoadjuvant therapy across different cancer diseases.
Over the past two days, we shared cutting-edge science, debated challenging clinical questions, and, most importantly, generated new ideas and collaborations that will help shape the future of cancer treatment.
The quality of the discussions and the enthusiasm of all participants once again confirmed that the neoadjuvant setting is becoming one of the most exciting areas of oncology, offering a unique opportunity to integrate clinical innovation with translational research.
A heartfelt thank you to our outstanding faculty, whose scientific excellence and willingness to openly exchange ideas made this meeting so stimulating.
My sincere gratitude also goes to our industry partners, whose support made this event possible, and to 3P Solution, especially Virginia Vighi and Mirella, for their exceptional professionalism and dedication in organizing every detail of the meeting.
Last, but certainly not least, my deepest thanks go to Prof Dr Christian Blank and Liz Burton. Their commitment to developing the scientific program and bringing together so many outstanding colleagues and friends from around the world was fundamental to the success of this edition.
We leave Naples inspired, with many new ideas and an even stronger determination to make INNOVATE 2027 even better. See you next year!”
Other articles featuring Paolo Ascierto.
